Intranasal compositions
AssigneeArchimedes Development Limited
InventorsPeter Watts, Yu-Hui Cheng
Life of this patent
Estimating the term…
Abstract
A liquid aqueous formulation for the intranasal administration of apomorphine includes: (a) at least about 15 mg/ml of apomorphine; and (b) a solubilising agent selected from (i) at least one polyoxyethylene-polyoxypropylene copolymer (poloxamer); (ii) at least one cyclodextrin; and (iii) at least one cyclodextrin together with chitosan. The formulations of the invention can be used in the treatment or management of Parkinson's disease and erectile dysfunction.
Claims23
1-30. (canceled)
A liquid aqueous formulation for the intranasal administration of apomorphine, which comprises:
- (a) at least about 15 mg/ml of apomorphine;
- and
- (b) a solubilising agent selected from
- (i) at least one polyoxyethylene-polyoxypropylene copolymer (poloxamer);
- (ii) at least one cyclodextrin;
- and
- (iii) at least one cyclodextrin together with chitosan.
A method of enhancing aqueous solubility of apomorphine, the method comprising mixing with apomorphine a solubilising agent selected from
- (i) at least one polyoxyethylene-polyoxypropylene copolymer (poloxamer);
- (ii) at least one cyclodextrin;
- and
- (iii) at least one cyclodextrin together with chitosan.
Dependencies are inferred from the claim text.